Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
To read the full story
Related Article
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026
- Chugai Files Enspryng for MOGAD Relapse Prevention in Japan
August 3, 2026
- Teijin Seeks Japan Nod for Ascendis’s GHD Drug
February 13, 2026
- Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
- J&J Seeks Pediatric UC Indication for Stelara in Japan
January 26, 2026
REGULATORY
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026
- MHLW Drug Supply Monitoring System Hit by Cyberattack, Possible Data Leak
November 19, 2026
- Expert Calls for Remote MRI Reviews to Monitor Alzheimer’s Drug Risks
November 18, 2026
- Japan Implements ICH Bioequivalence Guideline for Immediate-Release Oral Drugs
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





